Form 4: Amylyx Pharmaceuticals' Chief Legal Officer Sells Shares Under 10b5-1 Trading Plan
SEC Filing Form 4
Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, sold 10,455 shares of common stock at an average price of $1.8799 per share under a pre-arranged trading plan.
Summary
- Gina Mazzariello, the Chief Legal Officer of Amylyx Pharmaceuticals, sold 10,455 shares of common stock on May 15, 2024.
- The sales were executed under a Rule 10b5-1 trading plan adopted on December 14, 2023.
- The shares were sold at prices ranging from $1.82 to $1.92, with a weighted average price of $1.8799.
- Following the transaction, Mazzariello directly owns 151,477 shares of Amylyx Pharmaceuticals.
- The transaction was reported on a Form 4 filing with the Securities and Exchange Commission.
Sentiment
Score: 5
Explanation: Neutral sentiment as it is a routine disclosure of an insider transaction under a pre-arranged trading plan.
Industry Context
This is a routine disclosure of an insider transaction. It is common for executives to use 10b5-1 trading plans to sell shares over time to avoid accusations of trading on inside information. The impact on the stock is usually minimal unless the sale is very large.
Key Dates
| Date | Description |
|---|---|
| 2023-12-14 | Date of adoption of the Rule 10b5-1 trading plan. |
| 2024-05-15 | Date of the stock sale transaction. |
| 2024-05-16 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.